頁面路徑選單
- 首頁
- 市場技術報告
- 生命科學
- 生物科技 & 生物化學
- 報告資訊
CRISPR And CRISPR-Associated (Cas) Genes Market Analysis By Product (Vector-Based & DNA-Free Cas), By Application (Genome Engineering, Disease Models, Functional Genomics), By End-Use, And Segment Forecasts, 2014 - 2025
出 版 商：Grand View Research
出版日期：2017/01/31
頁 數：150頁
文件格式：PDF
價 格：
USD 4,950 (Single-User License)
USD 7,950 (Multi-User License)
USD 9,950 (Global-User License)
USD 7,950 (Multi-User License)
USD 9,950 (Global-User License)
The Clustered regularly interspaced short palindromic repeats CRISPR and CRISPR-associated (Cas) genes market is anticipated to reach USD 4.09 billion by 2025, according to a new report by Grand View Research, Inc. This genome editing principle spans almost every industry that involves biological systems. The rising adoption of technology in different areas associated with biotechnology is anticipated to drive industrial growth of the technology substantially in the coming years.
Possibility of rewriting the host DNA through the virtue of Cas9 by introduction of major modifications can be attributed for rising adoption of technology. These modifications include inversion, deletions, knockouts, translocations, and gene replacement.
Moreover, application of the technology as a qualitative as well as quantitative tool in plant genome editing is expected to propel growth. The technique holds the potential for producing plants with mutations linked to other disciplines of science such as disease resistance, biofuel production, synthetic biology, phytoremediation and abiotic stress tolerance.
Combination of clustered regularly interspaced short palindromic repeats and sequencing technology enables high-throughput analysis of gene regulation thereby resulting to enhancement in genomics sector. The aforementioned combination is applicable in the epigenetic study of diseases such as leukemia.
However, off-target effects associated with the implementation of CRISPR is anticipated to impede growth in the coming years. These effects include improper concentration ratio between Cas9 and single guide RNA that may result into off-target cleavage.
Further Key Findings from the Report Suggest:
High cost involved with mRNA and protein as compared to plasmid is attributive for larger share of vector based Cas9
Rapid turn-over obtained through the utilization of RNA and protein is anticipated to drive the usage of DNA free Cas9 products
Genome engineering dominated amongst the other applications as a consequence of higher use of Cas9 in different procedures
These procedures include Non-Homologous End Joining (NHEJ) and Homology Directed Repair (HDR) in plant genome editing and biomedical applications
Disease models and knockdown or activation are anticipated to witness hand in hand growth over the forecast period
Transgenic models are projected to witness lucrative growth as a result of application of technique for creation of novel in vivo neurodegenerative disease models
Biotechnology and pharmaceutical organizations accounted for the largest share of the market
These organizations are engaged in collaborating for the development of therapies using the Crispr-Cas9 gene-editing system
Asia Pacific is anticipated to witness lucrative growth over the forecast period.
The economies of this region are engaged in embarking clinical trials with the CRISPR gene-editing tool
Moreover, the university based projects implemented herein are attributive for the projected growth
Key players contributing in this market are Merck KGaA, Addgene, CRISPR THERAPEUTICS, Thermo Fisher Scientific, Inc., Mirus Bio LLC, Editas Medicine, Takara Bio USA, Horizon Discovery Group plc, GE Healthcare Dharmacon Inc, and Intellia Therapeutics, Inc.
These participants are pushing forward with development of CRIPSR-based therapies and some are expected to begin clinical development as early as next year.
Possibility of rewriting the host DNA through the virtue of Cas9 by introduction of major modifications can be attributed for rising adoption of technology. These modifications include inversion, deletions, knockouts, translocations, and gene replacement.
Moreover, application of the technology as a qualitative as well as quantitative tool in plant genome editing is expected to propel growth. The technique holds the potential for producing plants with mutations linked to other disciplines of science such as disease resistance, biofuel production, synthetic biology, phytoremediation and abiotic stress tolerance.
Combination of clustered regularly interspaced short palindromic repeats and sequencing technology enables high-throughput analysis of gene regulation thereby resulting to enhancement in genomics sector. The aforementioned combination is applicable in the epigenetic study of diseases such as leukemia.
However, off-target effects associated with the implementation of CRISPR is anticipated to impede growth in the coming years. These effects include improper concentration ratio between Cas9 and single guide RNA that may result into off-target cleavage.
Further Key Findings from the Report Suggest:
High cost involved with mRNA and protein as compared to plasmid is attributive for larger share of vector based Cas9
Rapid turn-over obtained through the utilization of RNA and protein is anticipated to drive the usage of DNA free Cas9 products
Genome engineering dominated amongst the other applications as a consequence of higher use of Cas9 in different procedures
These procedures include Non-Homologous End Joining (NHEJ) and Homology Directed Repair (HDR) in plant genome editing and biomedical applications
Disease models and knockdown or activation are anticipated to witness hand in hand growth over the forecast period
Transgenic models are projected to witness lucrative growth as a result of application of technique for creation of novel in vivo neurodegenerative disease models
Biotechnology and pharmaceutical organizations accounted for the largest share of the market
These organizations are engaged in collaborating for the development of therapies using the Crispr-Cas9 gene-editing system
Asia Pacific is anticipated to witness lucrative growth over the forecast period.
The economies of this region are engaged in embarking clinical trials with the CRISPR gene-editing tool
Moreover, the university based projects implemented herein are attributive for the projected growth
Key players contributing in this market are Merck KGaA, Addgene, CRISPR THERAPEUTICS, Thermo Fisher Scientific, Inc., Mirus Bio LLC, Editas Medicine, Takara Bio USA, Horizon Discovery Group plc, GE Healthcare Dharmacon Inc, and Intellia Therapeutics, Inc.
These participants are pushing forward with development of CRIPSR-based therapies and some are expected to begin clinical development as early as next year.
Table of Contents
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
Chapter 2 Executive Summary
Chapter 3 CRISPR and Cas Genes Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market Driver Analysis
3.1.1.1 Rising adoption in diverse fields of biotechnology
3.1.1.1.1 Epigenetics
3.1.1.1.2 Medicine
3.1.1.1.3 Human germline editing
3.1.1.1.4 Tool for qualitative and quantitative plant genome editing
3.1.1.2 Technological advancements in CRISPR technology
3.1.1.3 Introduction of anti-CRISPR protein
3.1.1.4 Ongoing competition for CRISPR commercialization
3.1.2 Market Restraint Analysis
3.1.2.1 Off-target effects of CRISPR technology
3.1.2.2 Intellectual property disputes pertaining to Cas
3.1.2.3 Ethical concerns and implications with respect to human genome editing
3.2 Penetration & Growth Prospect Mapping for Application, 2015
3.3 CRISPR and Cas Genes -Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter’s
3.5 CRISPR and Cas Genes Market: Pipeline Analysis
3.5.1 Editas Medicine
3.5.2 Intellia Therapeutics, Inc.
3.5.3 CRISPR THERAPEUTICS
3.5.4 Precision Biosciences
3.5.5 Caribou Biosciences
3.5.6 Cibus
3.5.7 Recombinetics, Inc
3.6 CRISPR and Cas Genes Market: Patent Landscape
Chapter 4 CRISPR and Cas Genes Market: Product Estimates & Trend Analysis
4.1 CRISPR and Cas Genes Market: Product Movement Analysis
4.2 Vector-based Cas
4.2.1 Global vector-based Cas market, 2014 - 2025 (USD Million)
4.3 DNA-free Cas
4.3.1 Global DNA-free Cas market, 2014 - 2025 (USD Million)
Chapter 5 CRISPR and Cas Genes Market: Application Estimates & Trend Analysis
5.1 CRISPR and Cas Genes Market: Application Movement Analysis
5.2 Genome Engineering
5.2.1 Global genome engineering market, 2014 - 2025 (USD Million)
5.3 Disease Models
5.3.1 Global disease models market, 2014 - 2025 (USD Million)
5.4 Functional Genomics
5.4.1 Global functional genomics market, 2014 - 2025 (USD Million)
5.5 Knockdown/Activation
5.5.1 Global knockdown/activation market, 2014 - 2025 (USD Million)
5.6 Others
5.6.1 Global other applications market, 2014 - 2025 (USD Million)
Chapter 6 CRISPR and Cas Genes Market: End-use Estimates & Trend Analysis
6.1 CRISPR and Cas Genes Market: End-use Movement Analysis
6.2 Biotechnology & Pharmaceutical Companies
6.2.1 Global biotechnology & pharmaceutical companies market, 2014 - 2025 (USD Million)
6.3 Academic & Government Research Institutes
6.3.1 Global academic & government research institutes market, 2014 - 2025 (USD Million)
6.4 Contract Research Organizations (CROs)
6.4.1 Global CROs market, 2014 - 2025 (USD Million)
Chapter 7 CRISPR and Cas Genes Market: Regional Estimates & Trend Analysis, by Product, Application, & End-use
7.1 CRISPR and Cas Genes Market Share By Region, 2015 & 2025
7.2 North America
7.2.1 North America CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.2.3 Canada
7.2.3.1 Canada CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.3 Europe
7.3.1 Europe CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.3.2 Germany
7.3.2.1 Germany CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.3.3 UK
7.3.3.1 UK CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.4.2 Japan
7.4.2.1 Japan CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.4.3 China
7.4.3.1 China CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.5 Latin America
7.5.1 Latin America CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.6 Middle East & Africa (MEA)
7.6.1 Middle East & Africa CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa CRISPR and Cas genes market, 2014 - 2025 (USD Million)
Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Market Participation Categorization
8.3 Company Profiles
8.3.1 Addgene
8.3.1.1 Company overview
8.3.1.2 Financial performance
8.3.1.3 Product benchmarking
8.3.1.4 Strategic initiatives
8.3.2 AstraZeneca
8.3.2.1 Company overview
8.3.2.2 Financial performance
8.3.2.3 Product benchmarking
8.3.2.4 Strategic initiatives
8.3.3 Bio-Rad Laboratories, Inc
8.3.3.1 Company overview
8.3.3.2 Financial performance
8.3.3.3 Product benchmarking
8.3.3.4 Strategic initiatives
8.3.4 Caribou Biosciences, Inc
8.3.4.1 Company overview
8.3.4.2 Financial performance
8.3.4.3 Product benchmarking
8.3.4.4 Strategic initiatives
8.3.5 Cellectis
8.3.5.1 Company overview
8.3.5.1.1 Calyxt
8.3.5.2 Financial performance
8.3.5.2.1 Financial performance
8.3.5.3 Product benchmarking
8.3.5.4 Strategic initiatives
8.3.6 Cibus
8.3.6.1 Company overview
8.3.6.1.1 Nucelis
8.3.6.2 Financial performance
8.3.6.2.1 Financial performance
8.3.6.3 Product benchmarking
8.3.6.4 Strategic initiatives
8.3.7 CRISPR THERAPEUTICS
8.3.7.1 Company overview
8.3.7.2 Financial performance
8.3.7.3 Product benchmarking
8.3.7.4 Strategic initiatives
8.3.8 Editas Medicine
8.3.8.1 Company overview
8.3.8.2 Financial performance
8.3.8.3 Product benchmarking
8.3.8.4 Strategic initiatives
8.3.9 Egenesis Inc.
8.3.9.1 Company overview
8.3.9.2 Financial performance
8.3.9.3 Product benchmarking
8.3.10 GE Healthcare Dharmacon Inc.
8.3.10.1 Company overview
8.3.10.2 Financial performance
8.3.10.3 Product benchmarking
8.3.10.4 Strategic initiatives
8.3.11 GenScript
8.3.11.1 Company overview
8.3.11.2 Financial performance
8.3.11.3 Product benchmarking
8.3.11.4 Strategic initiatives
8.3.12 Horizon Discovery Group plc
8.3.12.1 Company overview
8.3.12.2 Financial performance
8.3.12.3 Product benchmarking
8.3.12.4 Strategic initiatives
8.3.13 Integrated DNA Technologies, Inc.
8.3.13.1 Company overview
8.3.13.2 Financial performance
8.3.13.3 Product benchmarking
8.3.14 Intellia Therapeutics, Inc.
8.3.14.1 Company overview
8.3.14.2 Financial performance
8.3.14.3 Product benchmarking
8.3.14.4 Strategic initiatives
8.3.15 Lonza
8.3.15.1 Company overview
8.3.15.2 Financial performance
8.3.15.3 Product benchmarking
8.3.15.4 Strategic initiatives
8.3.16 Merck KGaA
8.3.16.1 Company overview
8.3.16.1.1 Sigma-Aldrich Co. LLC
8.3.16.2 Financial performance
8.3.16.2.1 Financial performance
8.3.16.3 Product benchmarking
8.3.16.4 Strategic initiatives
8.3.17 Mirus Bio LLC
8.3.17.1 Company overview
8.3.17.2 Financial performance
8.3.17.3 Product benchmarking
8.3.17.4 Strategic initiatives
8.3.18 New England Biolabs
8.3.18.1 Company overview
8.3.18.2 Financial performance
8.3.18.3 Product benchmarking
8.3.18.4 Strategic initiatives
8.3.19 OriGene Technologies, Inc.
8.3.19.1 Company overview
8.3.19.2 Financial performance
8.3.19.3 Product benchmarking
8.3.19.4 Strategic initiatives
8.3.20 Recombinetics, Inc.
8.3.20.1 Company overview
8.3.20.2 Financial performance
8.3.20.3 Product benchmarking
8.3.20.4 Strategic initiatives
8.3.21 Takara Bio USA
8.3.21.1 Company overview
8.3.21.2 Financial performance
8.3.21.3 Product benchmarking
8.3.21.4 Strategic initiatives
8.3.22 Thermo Fisher Scientific, Inc.
8.3.22.1 Company overview
8.3.22.2 Financial performance
8.3.22.3 Product benchmarking
8.3.22.4 Strategic initiatives
8.3.23 Transposagen Biopharmaceuticals, Inc.
8.3.23.1 Company overview
8.3.23.2 Financial performance
8.3.23.3 Product benchmarking
8.3.23.4 Strategic initiatives
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
Chapter 2 Executive Summary
Chapter 3 CRISPR and Cas Genes Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market Driver Analysis
3.1.1.1 Rising adoption in diverse fields of biotechnology
3.1.1.1.1 Epigenetics
3.1.1.1.2 Medicine
3.1.1.1.3 Human germline editing
3.1.1.1.4 Tool for qualitative and quantitative plant genome editing
3.1.1.2 Technological advancements in CRISPR technology
3.1.1.3 Introduction of anti-CRISPR protein
3.1.1.4 Ongoing competition for CRISPR commercialization
3.1.2 Market Restraint Analysis
3.1.2.1 Off-target effects of CRISPR technology
3.1.2.2 Intellectual property disputes pertaining to Cas
3.1.2.3 Ethical concerns and implications with respect to human genome editing
3.2 Penetration & Growth Prospect Mapping for Application, 2015
3.3 CRISPR and Cas Genes -Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter’s
3.5 CRISPR and Cas Genes Market: Pipeline Analysis
3.5.1 Editas Medicine
3.5.2 Intellia Therapeutics, Inc.
3.5.3 CRISPR THERAPEUTICS
3.5.4 Precision Biosciences
3.5.5 Caribou Biosciences
3.5.6 Cibus
3.5.7 Recombinetics, Inc
3.6 CRISPR and Cas Genes Market: Patent Landscape
Chapter 4 CRISPR and Cas Genes Market: Product Estimates & Trend Analysis
4.1 CRISPR and Cas Genes Market: Product Movement Analysis
4.2 Vector-based Cas
4.2.1 Global vector-based Cas market, 2014 - 2025 (USD Million)
4.3 DNA-free Cas
4.3.1 Global DNA-free Cas market, 2014 - 2025 (USD Million)
Chapter 5 CRISPR and Cas Genes Market: Application Estimates & Trend Analysis
5.1 CRISPR and Cas Genes Market: Application Movement Analysis
5.2 Genome Engineering
5.2.1 Global genome engineering market, 2014 - 2025 (USD Million)
5.3 Disease Models
5.3.1 Global disease models market, 2014 - 2025 (USD Million)
5.4 Functional Genomics
5.4.1 Global functional genomics market, 2014 - 2025 (USD Million)
5.5 Knockdown/Activation
5.5.1 Global knockdown/activation market, 2014 - 2025 (USD Million)
5.6 Others
5.6.1 Global other applications market, 2014 - 2025 (USD Million)
Chapter 6 CRISPR and Cas Genes Market: End-use Estimates & Trend Analysis
6.1 CRISPR and Cas Genes Market: End-use Movement Analysis
6.2 Biotechnology & Pharmaceutical Companies
6.2.1 Global biotechnology & pharmaceutical companies market, 2014 - 2025 (USD Million)
6.3 Academic & Government Research Institutes
6.3.1 Global academic & government research institutes market, 2014 - 2025 (USD Million)
6.4 Contract Research Organizations (CROs)
6.4.1 Global CROs market, 2014 - 2025 (USD Million)
Chapter 7 CRISPR and Cas Genes Market: Regional Estimates & Trend Analysis, by Product, Application, & End-use
7.1 CRISPR and Cas Genes Market Share By Region, 2015 & 2025
7.2 North America
7.2.1 North America CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.2.3 Canada
7.2.3.1 Canada CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.3 Europe
7.3.1 Europe CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.3.2 Germany
7.3.2.1 Germany CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.3.3 UK
7.3.3.1 UK CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.4.2 Japan
7.4.2.1 Japan CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.4.3 China
7.4.3.1 China CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.5 Latin America
7.5.1 Latin America CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.6 Middle East & Africa (MEA)
7.6.1 Middle East & Africa CRISPR and Cas genes market, 2014 - 2025 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa CRISPR and Cas genes market, 2014 - 2025 (USD Million)
Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Market Participation Categorization
8.3 Company Profiles
8.3.1 Addgene
8.3.1.1 Company overview
8.3.1.2 Financial performance
8.3.1.3 Product benchmarking
8.3.1.4 Strategic initiatives
8.3.2 AstraZeneca
8.3.2.1 Company overview
8.3.2.2 Financial performance
8.3.2.3 Product benchmarking
8.3.2.4 Strategic initiatives
8.3.3 Bio-Rad Laboratories, Inc
8.3.3.1 Company overview
8.3.3.2 Financial performance
8.3.3.3 Product benchmarking
8.3.3.4 Strategic initiatives
8.3.4 Caribou Biosciences, Inc
8.3.4.1 Company overview
8.3.4.2 Financial performance
8.3.4.3 Product benchmarking
8.3.4.4 Strategic initiatives
8.3.5 Cellectis
8.3.5.1 Company overview
8.3.5.1.1 Calyxt
8.3.5.2 Financial performance
8.3.5.2.1 Financial performance
8.3.5.3 Product benchmarking
8.3.5.4 Strategic initiatives
8.3.6 Cibus
8.3.6.1 Company overview
8.3.6.1.1 Nucelis
8.3.6.2 Financial performance
8.3.6.2.1 Financial performance
8.3.6.3 Product benchmarking
8.3.6.4 Strategic initiatives
8.3.7 CRISPR THERAPEUTICS
8.3.7.1 Company overview
8.3.7.2 Financial performance
8.3.7.3 Product benchmarking
8.3.7.4 Strategic initiatives
8.3.8 Editas Medicine
8.3.8.1 Company overview
8.3.8.2 Financial performance
8.3.8.3 Product benchmarking
8.3.8.4 Strategic initiatives
8.3.9 Egenesis Inc.
8.3.9.1 Company overview
8.3.9.2 Financial performance
8.3.9.3 Product benchmarking
8.3.10 GE Healthcare Dharmacon Inc.
8.3.10.1 Company overview
8.3.10.2 Financial performance
8.3.10.3 Product benchmarking
8.3.10.4 Strategic initiatives
8.3.11 GenScript
8.3.11.1 Company overview
8.3.11.2 Financial performance
8.3.11.3 Product benchmarking
8.3.11.4 Strategic initiatives
8.3.12 Horizon Discovery Group plc
8.3.12.1 Company overview
8.3.12.2 Financial performance
8.3.12.3 Product benchmarking
8.3.12.4 Strategic initiatives
8.3.13 Integrated DNA Technologies, Inc.
8.3.13.1 Company overview
8.3.13.2 Financial performance
8.3.13.3 Product benchmarking
8.3.14 Intellia Therapeutics, Inc.
8.3.14.1 Company overview
8.3.14.2 Financial performance
8.3.14.3 Product benchmarking
8.3.14.4 Strategic initiatives
8.3.15 Lonza
8.3.15.1 Company overview
8.3.15.2 Financial performance
8.3.15.3 Product benchmarking
8.3.15.4 Strategic initiatives
8.3.16 Merck KGaA
8.3.16.1 Company overview
8.3.16.1.1 Sigma-Aldrich Co. LLC
8.3.16.2 Financial performance
8.3.16.2.1 Financial performance
8.3.16.3 Product benchmarking
8.3.16.4 Strategic initiatives
8.3.17 Mirus Bio LLC
8.3.17.1 Company overview
8.3.17.2 Financial performance
8.3.17.3 Product benchmarking
8.3.17.4 Strategic initiatives
8.3.18 New England Biolabs
8.3.18.1 Company overview
8.3.18.2 Financial performance
8.3.18.3 Product benchmarking
8.3.18.4 Strategic initiatives
8.3.19 OriGene Technologies, Inc.
8.3.19.1 Company overview
8.3.19.2 Financial performance
8.3.19.3 Product benchmarking
8.3.19.4 Strategic initiatives
8.3.20 Recombinetics, Inc.
8.3.20.1 Company overview
8.3.20.2 Financial performance
8.3.20.3 Product benchmarking
8.3.20.4 Strategic initiatives
8.3.21 Takara Bio USA
8.3.21.1 Company overview
8.3.21.2 Financial performance
8.3.21.3 Product benchmarking
8.3.21.4 Strategic initiatives
8.3.22 Thermo Fisher Scientific, Inc.
8.3.22.1 Company overview
8.3.22.2 Financial performance
8.3.22.3 Product benchmarking
8.3.22.4 Strategic initiatives
8.3.23 Transposagen Biopharmaceuticals, Inc.
8.3.23.1 Company overview
8.3.23.2 Financial performance
8.3.23.3 Product benchmarking
8.3.23.4 Strategic initiatives
